Former Deputy Secretary of Australia’s Department of Health & Aged Care, and Head of the Therapeutic Goods Administration (TGA), Professor Skerritt joins Wintermute's Board of Directors to strengthen regulatory and strategic leadership.
Learn More
Advancing SolexanTM, a proprietary topical antiviral platform treatment for shingles infections.
Phase Ib trial completed demonstrating safety and tolerability.
Patent and trademark protection across key markets.
ZosterEaseTM trial to address the global shingles market.
Based in Melbourne, Australia and Missoula, USA.
ZosterEaseTM trial to address the existing treatment shortfall for shingles infections.
ZosterEaseTM trial to address the existing treatment shortfall for shingles infections.
ZosterEaseTM trial to address the existing treatment shortfall for shingles infections.
Wintermute Biomedical strengthens its board credentials with the announcement of Prof. Skerritt, former head of Australia's Therapeutic Goods Administration.
World's first validated, lab-based model of oral gonorrhoea infection using human oral cells
Clinical trial's full patient number recruitment moves Solexan™ forward as a new therapy option for shingles sufferers, a debilitating and painful viral infection.
Simply fill out the form to download our Investor Deck materials or reach out to our team.
Information is for investors and potential partners; not for promotional use.
Thank you, your form has been received.
